In vivo Tumor Models
In vivo Tumor Models
Bladder | Brain | Breast | Colorectal | Head & Neck | Kidney | Liver | Lung | Lymphoma
Bladder Cancer Models
Model Type: Xenograft
Partner with us to explore how these bladder cancer models can accelerate your oncology program. Our team ensures precision and customization to meet your research needs. Request a quote →
UMUC3
A widely used bladder cancer cell line ideal for evaluating the efficacy of therapeutics targeting urothelial carcinoma. UMUC3 is known for its aggressive phenotype and reproducible growth in xenograft models, making it an excellent choice for drug screening studies.
HT1376
This high-grade bladder cancer cell line is frequently employed to study tumor progression and therapeutic response in invasive bladder cancers.
5637
A reliable model for non-invasive bladder cancer studies, commonly used in immuno-oncology research to evaluate immune-targeted therapies.
Brain Cancer (Glioma) Models
U87 MG
One of the most well-characterized glioblastoma cell lines, ideal for investigating the efficacy of therapies targeting aggressive brain tumors. U87 MG is particularly useful for studying blood-brain barrier permeability and therapeutic delivery.
GL261
A syngeneic glioma model in C57BL/6 mice, this immunocompetent model is excellent for evaluating immune-based therapies, including checkpoint inhibitors and CAR-T cells.
Model Types: Xenograft, Syngeneic (C57BL/6)
Let us help you design impactful studies using these glioma models to better understand therapeutic responses in the context of brain cancer. Request a quote →
Breast Cancer Models
MDA-MB-231
A triple-negative breast cancer model known for its high invasiveness and metastatic potential, making it ideal for studying aggressive tumor phenotypes and therapeutic interventions.
BT474
An HER2-positive breast cancer model frequently utilized in targeted therapy development, particularly HER2 inhibitors.
HCC1954
A robust HER2-positive model, useful for testing combination therapies involving HER2-targeted and chemotherapeutic agents.
4T1
A syngeneic model in Balb/C mice that mimics metastatic breast cancer, ideal for immuno-oncology studies.
Model Types: Xenograft, Syngeneic
Contact us today to discuss how our breast cancer models can advance your preclinical research and provide clinically relevant insights.
Colorectal Cancer Models
HT-29
A human colorectal adenocarcinoma model known for its well-differentiated characteristics, commonly used in drug efficacy and resistance studies.
COLO-205
A metastatic colorectal cancer model ideal for evaluating therapeutic agents targeting advanced disease stages.
SW620
A lymph node metastatic model, frequently used to investigate metastasis and therapeutic responses.
CT26
A syngeneic model in Balb/C mice, widely used for immunotherapy studies in colorectal cancer.
Model Types: Xenograft, Syngeneic
Our colorectal cancer models offer unparalleled opportunities for studying drug efficacy and tumor biology. Let us help you achieve your research goals. Request a quote →
Head and Neck Cancer Models
FaDu
A hypopharyngeal squamous cell carcinoma model ideal for studying head and neck cancers. FaDu is frequently used for radiation and chemotherapy studies.
A253
A salivary gland carcinoma model, providing insights into rare tumor types and testing targeted therapies.
KB
A model for oral squamous cell carcinoma, commonly used to evaluate therapeutic efficacy and resistance mechanisms.
Model Types: Xenograft, Syngeneic
Collaborate with us to leverage these head and neck cancer models for precision-focused preclinical studies.
Request a quote →
Kidney Cancer Models
786-0
A clear cell renal cell carcinoma model that is highly responsive to VEGF/VEGFR targeted therapies, making it an excellent choice for drug development in kidney cancer.
Model Type: Xenograft
Take advantage of Noble’s expertise to accelerate your renal cancer research with highly characterized models. Request a quote →
Liver Cancer Models
MHCC97H
A metastatic liver cancer model, suitable for studying aggressive phenotypes and therapeutic resistance.
Huh-7
A hepatocellular carcinoma model widely used for antiviral and liver cancer therapeutic studies
HepG3 & HepG2
Models for studying drug metabolism, liver cancer progression, and testing chemotherapeutics.
Model Type: Xenograft
We deliver actionable data through our liver cancer models to support your therapeutic development programs.
Request a quote →
Lung Cancer Models
H-460
A large cell lung carcinoma model, ideal for testing chemotherapies and combination regimens.
A549
A non-small cell lung cancer (NSCLC) model extensively used for studying tumor biology and therapeutic responses.
Lewis Lung
A syngeneic model in C57BL/6 mice, providing valuable insights into immunotherapy strategies.
Model Types: Xenograft, Syngeneic
Maximize your lung cancer research outcomes with our comprehensive models and expert support.
Request a quote →
Lymphoma Models
Raji
A Burkitt’s lymphoma model frequently used for immune-targeted therapies, including CAR-T and monoclonal antibodies.
U937
A histiocytic lymphoma model for studying both tumor biology and therapeutic efficacy.
Model Type: Xenograft
Patient-Derived Xenograft (PDX) Models
PDX models provide the most clinically relevant insights into human cancer biology. At Noble, we offer PDX models for:
- Brain
- Breast
- Lung
- Colorectal
- Pancreatic
Our PDX models retain the histological and genetic characteristics of the original patient tumor, enabling highly translational data for drug development.
In vivo Tumor Models
Noble Life Sciences is your trusted partner for oncology research, delivering high-quality, customizable tumor models tailored to your study needs.
Contact us today to discuss your project and learn how our models can help achieve your research goals.
Scientific Advisor Team
Our oncology team is committed to fight The Fight
by advancing your preclinical research.
Stephen K. Horrigan, Ph.D.
Chief Scientific Officer
Pang-Kuo Lo, Ph.D. MSc
Vice President, Study and Assay Operations
Arundhati Ghosh, Ph.D., MSc
Study Director
Yongping Chen, M.D., Ph.D.
Senior Director, Pharmacology